Rhythm Pharmaceuticals
Rhythm Pharmaceuticals Inc is an American commercial-stage biopharmaceutical company focused on rare genetic diseases of obesity. The company discovers, develops, and commercializes therapies targeting the melanocortin-4 receptor pathway to restore energy balance in patients with hyperphagia and severe obesity. Main revenue drivers stem from sales of setmelanotide, marketed under the brand name Imcivree, for conditions such as Bardet-Biedl syndrome and pro-opiomelanocortin deficiency. Rhythm Pharmaceuticals serves specialized medical markets, healthcare providers, and patients across North America, Europe, and international territories. The company occupies a pioneer position in precision medicine for rare genetic endocrine disorders. Headquartered in Boston, Massachusetts, Rhythm Pharmaceuticals Inc is listed on the Nasdaq Stock Market.
8 of the funds FundTelligence covers report a position in Rhythm Pharmaceuticals.
- Legal name
- Rhythm Pharmaceuticals Inc
- Sector
- Health Care
- Country
- United States
- Funds holding it
- 8
- Exposure themes
- Genetic Obesity, Obesity, Obesity & Metabolic Health
Funds holding Rhythm Pharmaceuticals
- Polar Capital Biotechnology Fund — Polar Capital · 3.8 % (largest positions only, October 2026)
- DNB Bioteknologi — DNB · 3.51 % (full portfolio disclosed, September 2026)
- JPM US Small Cap Growth Fund — JPM · 1.19 % (full portfolio disclosed, June 2026)
- BlackRock iShares Healthcare Innovation UCITS ETF — BlackRock · 0.68 % (full portfolio disclosed, October 2026)
- BlackRock iShares NASDAQ US Biotechnology UCITS ETF — BlackRock · 0.5 % (full portfolio disclosed, October 2026)
- Handelsbanken Global SMB Index Criteria — Handelsbanken · 0.06 % (full portfolio disclosed, October 2026)
- KLP AksjeGlobal Small Cap Indeks — KLP · 0.06 % (partially disclosed portfolio, June 2026)
- DNB Global Enhanced Small Cap — DNB · 0.02 % (full portfolio disclosed, September 2026)